I'm going to start the answer, and then I'll ask my colleague to add more details.
We have an annual, multi-year mechanism that allows us to monitor our costs and know what they are associated with, in order to predict future costs. In addition, we examine whether the demand for drugs is similar for other public and private plans.
In order to project future costs, take action and make good decisions, we are studying the prevalence of certain diseases in the population we serve. Yes, the profile of its needs is often different.
After a period of relatively moderate growth in drug costs, we are now seeing an increase. This is happening this year and will continue over the next few years. This is mainly due to the new therapies on the market. For example, last year or two years ago, new hepatitis C therapies have emerged and this has had a significant impact on our public plan as well as a number of other plans across the country.